Literature DB >> 35105220

Evaluating xanthochromia in the diagnosis of subarachnoid haemorrhage in Scotland in the Era of modern computed tomography.

Stephen Rankin1,2, Jacqueline McGuire3, Mohamed Chekroud4, Likhith Alakandy5, Babu Mukhopadhyay2,6.   

Abstract

AIM: Cerebrospinal fluid (CSF) analysis for xanthochromia is routinely used to exclude subarachnoid haemorrhage (SAH). In this study, we evaluated the sensitivity and specificity of xanthochromia (by NEQAS-spectrophotometry) in routine clinical practice in three acute hospitals, in patients with suspected SAH. We explored whether including CSF red cell count (RCC) with xanthochromia improved diagnostic accuracy.
METHODS: In this retrospective analysis, all xanthochromia results were assessed over three consecutive years. Clinical information and Registry data were analysed to find all patients diagnosed with SAH. We correlated xanthochromia data with clinical and radiological findings.
RESULTS: There were 1761 xanthochromia performed. Of these, 26 (1.5%) were positive, 1624 (92%) negative and 72 (4.1%) were inconclusive. Of the 26 tests that were positive, 9 (35%) had confirmed SAH, 17 (65%) were falsely positive, with no false negative tests in our series. Xanthochromia identified 6% of all SAH diagnosed in the study. Incorporating RCC <1000 with xanthochromia, reducing false positive tests by 38% and inconclusive test by 85%.
CONCLUSION: The positive yield of xanthochromia is low but identified 6% of SAH. NEQAS-spectrophotometry is an excellent diagnostic method with 100% sensitivity, 99% specificity. Incorporating RCC markedly reduces false positive and inconclusive tests reducing need for further imaging.

Entities:  

Mesh:

Year:  2022        PMID: 35105220     DOI: 10.1177/00369330211072264

Source DB:  PubMed          Journal:  Scott Med J        ISSN: 0036-9330            Impact factor:   0.729


  1 in total

1.  Surgical skills and COVID-19 pandemic: Impact and way forward.

Authors:  Ghulam Nabi
Journal:  Scott Med J       Date:  2022-05       Impact factor: 2.426

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.